Congratulations! A recombinant protein medicine for diabetic wound treatment has received TFDA approval for Phase II clinical trials!

In June 2023, the professional team from VCRO assisted the client in submitting the clinical trial application of their recombinant protein product for the treatment of diabetic lower limb or foot ulcers. The team successfully obtained TFDA approval to proceed with Phase II clinical trials. We successfully supported our clients in smoothly advancing to the Phase II clinical trial stage. VCRO is here to accompany you through every stage of the clinical trial process.